Skip to main content
SpringerLink
Log in

Biological basis of anxiety and strategies for pharmacological innovation

  • Chapter
Anxiety Disorders

  • 421 Accesses

Abstract

Very little is known about the biological basis of anxiety disorder. Variance in personality traits, including those related to anxiety, is thought to be generated by a complex interaction of environmental and experiential factors with a number of gene products involving distinct brain systems such as the midbrain raphe serotonin (5-hydroxytryptamine, 5-HT) system (Loehlin, 1989; Plomin et al., 1994). Although twin studies have indicated that individual variation in measures of anxiety-related personality traits is 40-60% heritable, none of the relevant genes has yet been identified (Loehlin, 1989).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M & Curtis GC. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 48, 157–162, 1991

    PubMed  CAS  Google Scholar 

  • Ackerman DL, Greenland S, Bystritsky A, Morgenstern H & Katz RJ. Predictors of treatment response in obsessive-compulsive disorder: Multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 14, 247–254, 1994

    PubMed  CAS  Google Scholar 

  • Agmo A, Galvan A, Heredia A & Morales M. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology 120, 186–194, 1995

    PubMed  CAS  Google Scholar 

  • Albus M, Zahn TP & Breier A. Anxiogenic properties of yohimbine: I. Behavioral, physiological and biochemical measures. Eur Arch Psychiatry and Clin Neurosci 241, 337–344, 1992

    CAS  Google Scholar 

  • Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ & Papoport JL. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51, 794–803, 1994

    PubMed  CAS  Google Scholar 

  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Press, Washington, DC, 1994

    Google Scholar 

  • Andrews G, Stewart G, Allen R & Henderson AS. The genetics of six neurotic disorders: a twin study. J Affect Disord 19, 2396, 1990

    Google Scholar 

  • Balster RL. Perception of drug effects. In: MA Berkley & WC Stebbins (eds): Comparative perception, Vol. 1. New York: John Wiley and Sons, 127, 1990

    Google Scholar 

  • Balster RL & Willetts. Receptor mediation of the discriminative stimulus properties of phencyclidine and sigma opioid agonists. In: FC Coplaert & RL Balster (eds): Transduction mechanisms of drug stimuli. Berlin: Springer-Verlag, 122, 1988

    Google Scholar 

  • Barrett JE, Witkin JM, Mansbach RS, Skolnick P & Weissman BA. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. J Pharmacol Exp Ther 238, 1009–1013, 1986

    PubMed  CAS  Google Scholar 

  • Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN & Langer SZ. International Union of Pharmacology XV, subtypes of y-aminobutyric acidA receptors: Classification on the basis of subunit structure and receptor function. Pharmacol Rev 50 (2), 291–313, 1998

    PubMed  CAS  Google Scholar 

  • Bass EW Jr, Means LW & McMillen BA. Buspirone impairs performance of a three-choice working memory water escape task in rats. Brain Res Bull 28(3): 455–461, 1992

    PubMed  CAS  Google Scholar 

  • Baulieu EE. Steroid hormones in the brain: several mechanisms? In: K Fuxe, JA Gustafsson & L Wetterberg (eds): Steroid hormone regulation of the brain. Wenner-Gren Center International Symposium Series, Vol. 34. Oxford: Pergamon, 3–14, 1981

    Google Scholar 

  • Baulieu EE & Robel P. Neurosteroids: a new brain function? J Steroid Biochem Mol Biol 37, 395–403, 1990

    PubMed  CAS  Google Scholar 

  • Beekman M, Ungard JT, Gasior M, Carter RB, Dijkstra D, Goldberg SR & Witkin JM. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J Pharmacol Exp Ther 284(3): 868–877, 1998

    PubMed  CAS  Google Scholar 

  • Belzung C & Agmo A. Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not in BALB/c mice. Psychopharmacology 132, 195–201, 1997

    PubMed  CAS  Google Scholar 

  • Birbaumer N, Grodd W, Diedrich O, Klose U, Erb E, Lotze M et al. fMRI reveals amygdala activation to human faces in social phobics. Neuroreport 9, 1223–1226, 1998

    PubMed  CAS  Google Scholar 

  • Bitran D, Hilvers RJ & Kellogg CK. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 561(1): 157–161, 1991

    PubMed  CAS  Google Scholar 

  • Bormann J. Electrophysiology of GABAA and GABAB receptor subtypes. Trends Neurosci 11, 112–116, 1988

    PubMed  CAS  Google Scholar 

  • Boulenger JP, Jerabek I, Jolicoeur FB, Lavallee YJ, Leduc R & Cadieux A. Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am J Psychiatry 153, 114–116, 1996

    PubMed  CAS  Google Scholar 

  • Bowery NG, Hill DR, Hudson AL, Doble A, Middlemiss DN, Shaw J & Turnbull MJ. (-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel receptor. Nature 283, 92, 1980

    PubMed  CAS  Google Scholar 

  • Bowery NG, Doble A, Hill DR, Hudson AL, Shaw JS, Turnbull MJ & Warrington R. Bicuculline-insensitive GABA receptors on peripheral autonomic nerve terminals. Eur J Pharmacol 71, 53–70, 1981

    PubMed  CAS  Google Scholar 

  • Bowery NG. GABAB receptors and their significance in mammalian pharmacology. Trends Pharmacol Sci 10, 401–407, 1989

    PubMed  CAS  Google Scholar 

  • Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Arch Gen Psychiatry 48, 603–610, 1991

    PubMed  CAS  Google Scholar 

  • Britton KT, Southerland S, VanUden E, Kirby D, Rivier J and Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology 132, 6–13, 1997

    PubMed  CAS  Google Scholar 

  • Broqua P, Wettstein JG, Rocher MN, Gauthiermartin B and Junien JL. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6, 215–222, 1995

    PubMed  CAS  Google Scholar 

  • Brot MD, Akwa Y, Purdy RH, Koob GF & Britton KT. The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol 325 (1): 1–7, 1997

    PubMed  CAS  Google Scholar 

  • Brown SL, Svrakic MD, Przybeck TR & Cloninger CR. The relationship of personality to mood and anxiety states: a dimensional approach. J Psychiatry Res 26, 197–211, 1992

    CAS  Google Scholar 

  • Carlsson KR & Seeger TF. Interaction of opiates with dopamine receptors: receptor binding and behavioral assays: Pharmacol Biochem Behav 16, 119–124, 1982

    Google Scholar 

  • Chalmers DT, Lovenberg TW & De Souza EB. Localization of novel corticotropin-releasing factor (CRF2) mRNA expression to specific sub-cortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 15, 6340–6350, 1995

    PubMed  CAS  Google Scholar 

  • Chang CP, Pearse II RV, O’Connell S & Rosenfeld MG. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 11, 1187–1195, 1993

    PubMed  CAS  Google Scholar 

  • Charney DS, Heninger GR & Redmond DE. Yohimbine induced anxiety and increased noradrenergic function in humans: Effects of diazepam and clonidine. Life Sci 33, 19–29, 1983

    PubMed  CAS  Google Scholar 

  • Chaouloff F. Regulation of 5-HT receptors by corticosteroids: Where do we stand? Fundam Clin Pharmacol 9, 219–233, 1995

    CAS  Google Scholar 

  • Chen R, Lewis KA, Perrin MH & Vale WW. Expression cloning of a human corticotropinreleasing-factor. Proc Natl Acad Sci USA 8967–8971, 1993

    Google Scholar 

  • Chopin P & Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110, 409–414,1993

    PubMed  CAS  Google Scholar 

  • Cloninger CR. A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 44 (6): 573–588, 1987

    PubMed  CAS  Google Scholar 

  • Cloninger CR. A unified biosocial theory of personality and its role in the development of anxiety states: a reply to commentaries. Psychiatric Developments 6 (2): 83–120, 1988

    PubMed  CAS  Google Scholar 

  • Collier DA, Stöber G, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1, 453–460, 1996

    PubMed  CAS  Google Scholar 

  • Comings DE, Muhleman D, Johnson P & MacMurray JP. Potential role of the estrogen receptor gene (ESR1) in anxiety. Mol Psychiatry 4, 374–377, 1999

    PubMed  CAS  Google Scholar 

  • Copian JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, Liebowitz MR & Gorman JM. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry Vol 152(4), 619–622, 1995.

    Google Scholar 

  • Corbett R & Dunn RW. Effects of HA-966 on conflict, social interaction, and plus maze behaviors. Drug Development Research 24 (3), 201–205, 1991

    CAS  Google Scholar 

  • Corda MG, Giorgio O, Gatta F & Biggio G. Long-lasting proconflict effect induced by chronic administration of the beta-carboline derivation FG 7142. Neurosci Lett 62, 237–240, 1985

    PubMed  CAS  Google Scholar 

  • Corpechot C, Synguelakis M, Talha S, Axelson M, Sjovall J, Vihko R, Baulieu EE & Robel P. Pregnenolone and its sulfate ester in the rat brain. Brain Res 270, 119–125, 1983

    PubMed  CAS  Google Scholar 

  • Coryell W, Noyes R Jr & Schlechte J. The significance of HPA axis disturbance in panic dis-order. Biol Psychiatry 25, 989–1002, 1989

    PubMed  CAS  Google Scholar 

  • Costal B, Domemey AM, Hughes J, Kelly ME, Naylor RJ & Woodruff GN. Anxiolytic effects of CCK-B antagonists. Neuropeptides 19, 65–73, 1991

    Google Scholar 

  • Crawley JN, Glowa JR, Majewska MD & Paul SM. Anxiolytic activity of an endogenous adrenal steroid. Brain Res 398 (2): 382–385, 1986

    PubMed  CAS  Google Scholar 

  • Crestani F, Loez M, Baer K, Essrich V, Benke D, Laurent JP, Belzung C, Fristchy J-M, Luscher B & Mohler H. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nature Neurosci 2, 833–839, 1999

    PubMed  CAS  Google Scholar 

  • Criswell HE, DJ Knapp DH, Overstreet & GR Breese. Effects of ethanol, chlordiazepoxide and MK-801 on performance in the elevated-plus maze and on locomotor activity. Alcohol Clin Exp Res 18, 596, 1994

    PubMed  CAS  Google Scholar 

  • Critchley MA & Handley SL. Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology 93 (4): 502–506, 1987

    PubMed  CAS  Google Scholar 

  • Daugé V, Ladurelle N, Derrien M, Durieux C & Roques BR Potential therapeutic application of CCK antagonists in anxiety and panic disorders. In: M Hamon, H Ollat, M-H Thiébot (eds): Anxiety: Neurobiology, clinic and therapeutic perspectives. Colloque INSERM, Vol. 232. John Libbey EuroText Ltd, 167–176, 1993

    Google Scholar 

  • Davidson RJ, Marshall JR, Tomarken AJ & Henriques JB. While a phobic waits: Regional brain electrical and autonomic activity in social phobics during anticipation of public speaking. Biol Psychiatry 47, 85–95, 2000

    PubMed  CAS  Google Scholar 

  • Davis M. The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 13, 35–41, 1992

    PubMed  CAS  Google Scholar 

  • DeLorey TM & Olsen RW. γ-Aminobutyric acidA receptor structure and function. J Biol Chem 267, 16747–16750, 1992

    PubMed  CAS  Google Scholar 

  • de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings. Arch Gen Psychiatry 46, 511–517, 1989

    PubMed  Google Scholar 

  • DeRossett SE & Holzman SG. Effects of opiate antagonists and putative k agonists on unpunished and punished operant behavior in the rat. Psychopharmacology 86, 386–391, 1985

    PubMed  CAS  Google Scholar 

  • De Souza EB. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology 20, 789–819, 1995

    PubMed  Google Scholar 

  • Detari L, Szentgyorgyi V, Hajnik T, Szenasi G, Gacsalyi I & Kukorelli T. Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats. Psychopharmacology 142 (3), 318–326, 1999

    PubMed  CAS  Google Scholar 

  • De Vry J. 5HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121, 1–26, 1995

    PubMed  Google Scholar 

  • De Vry J. 5HT1A receptors in psychopathology and the mechanism of action of clinically effective therapeutic agents. Drug News Perspect 9, 270–280, 1996

    Google Scholar 

  • Dorow R, Horowski R, Paschelke G, Amin M & Brarstrup C. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptor. Lancet 41, 98–99, 1983

    Google Scholar 

  • Duncalfe LL, Carpenter MR, Smilie LB, Martin LL & Dunn MS. J Biol Chem 27,9209–9214, 1996

    Google Scholar 

  • Dunn RW, R Corbett & Fielding S. Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 169, 1, 1989

    PubMed  CAS  Google Scholar 

  • Duka T, Milian MJ, Ulsamer B, Doenicke A. Naloxone attenuates the anxiolytic action of diazepam in man. Life Science, 31, 1833–1836, 1982

    CAS  Google Scholar 

  • Dykstra LA, Preston KL & Bigelow GE. Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology 130 (1): 14–27, 1997

    PubMed  CAS  Google Scholar 

  • Edgar DM, Seidel WF, Gee KW, Lan NC, Field G, Xia H, Hawkinson JE, Wieland S, Carter RB & Wood PL. CCD-3693: an orally bioavailable analog of the endogenous neuroactive steroid, pregnanolone, demonstrates potent sedative hypnotic actions in the rat. J Pharmacol Exp Ther 282 (1): 420–429, 1997

    PubMed  CAS  Google Scholar 

  • Ennis MD. The therapeutic potential of 5-HT1A agonists. Curr Opin Invest Drugs 4, 205–213, 1993

    Google Scholar 

  • Davis EZ, Harris CR, Ellingson RJ, Andreason P, Moore V, Varner JL, Brown GL, Eckardt MJ & Goldman D. Relationship of genetically transmitted alpha EEG traits to anxiety disorders and alcoholism. Am J Med Genet Neuropsychiatric Genetics 60 (5), 400–408, 1995.

    Google Scholar 

  • Enz R & Cutting GR. Molecular composition of GABAC receptors. Vis Res 38, 1431–1441, 1998

    PubMed  CAS  Google Scholar 

  • Faludi G, Tekes K & Tothfalusi L. Comparative study of platelet 3H-paroxetine and 3Himipramine binding in panic disorder patients and healthy controls. J Psychiatry Neurosci 19 (2): 109–113, 1994

    PubMed  CAS  Google Scholar 

  • Feigenspan A & Bormann J. GABA-gated Cl-channels in the rat retina. Prog Retinal Eye Res 17, 99–126, 1998

    CAS  Google Scholar 

  • Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry 60 (22):18–22, 1999

    PubMed  CAS  Google Scholar 

  • Fernandez-Guasti A & Hong E. Antianxiety effect of various putative S1 receptor agonists on the conditioned defensive-burying paradigm. In: P Evans, AR Archer, T Archer (eds): Behavioral pharmacology of 5-HT. Hillsdale, NJ: Lawrence Erlbaum, 377–382, 1989

    Google Scholar 

  • Fernandez-Guasti A & Lopez-Rubalcava C. Modification of the anxiolytic action of 5-HT1A compounds by GABA-benzodiazepine agents in rats. Pharmacol Biochem Behav 60, 1, 27–32, 1998

    PubMed  CAS  Google Scholar 

  • Fernandez-Guasti A & Lopez-Rubalcava C. Action of ipsapirone and 8-OH-DPAT on exploratory behavior in hamsters (Mesocricetus auratus): Effects of antagonists and p-CPA. Pharmacol Biochem Behav 50, 375–382, 1995

    PubMed  CAS  Google Scholar 

  • Fink H, Rex A & Marsden CA. Behavioural and neurochemical effects of CCK-fragments in animal models of anxiety. Behav Pharmacol 5 (1), 30, 1994

    Google Scholar 

  • Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ et al. Behav Brain Res 73, 337–353, 1996

    PubMed  CAS  Google Scholar 

  • Flint J & Corley R. Do animal models have a place in the genetic analysis of quantitative human behavioural traits. J Mol Med 74, 515–521, 1996

    PubMed  CAS  Google Scholar 

  • Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y & Fletcher A. A pharmacological profile of the selective silent 5-HT1A receptor antagonist WAY-100635. Eur J Pharmacol 281, 81–88, 1995

    PubMed  CAS  Google Scholar 

  • Frye CA & Lacey EH. The neurosteroids DHEA and DHEAS may influence cognitive performance by altering affective state. Physiol Behav 66 (1), 85–92, 1999

    PubMed  CAS  Google Scholar 

  • Fuxe K, Andersson K, Locatelli V, Agnati LF, Hokfelt T, Skirboll L & Mutt V. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. Eur J Pharmacol 67, 329–331, 1980

    PubMed  CAS  Google Scholar 

  • Gallager DW. Benzodiazepines: Potentiation of a GABA inhibitory response in the dorsal raphe nucleus. Eur J Pharmacol 49, 133–143, 1978

    PubMed  CAS  Google Scholar 

  • Gavish M, Katz Y, Bar-Ami S & Weizman R. Biochemical, physiological, and pathological aspects of the peripheral aspects of the peripheral benzodiazepine receptor. J Neurochem 58, 1589–1601, 1992

    PubMed  CAS  Google Scholar 

  • Gavish M, Laor N, Bidder M, Fisher D, Fonia O, Muller U, Reiss A, Wolmer L, Karp L & Weizman R. Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder. Neuropsychopharmacology 14, 181–186, 1996

    PubMed  CAS  Google Scholar 

  • George DT, Nutt DJ, Rawlings RR, Phillips MJ, Exkart MJ, Potter WZ & Linnoila M. Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism. Biol Psychiatry 37, 112–119, 1995

    PubMed  CAS  Google Scholar 

  • Glaser T & De Vry J. Neurobiology of 5-HT1A receptors. In: SM Stahl, M Gastpar, JM Keppel Hesselink & J Traber (eds): Serotonin1A receptors in depression and anxiety. New York: Raven Press, 35–53, 1992

    Google Scholar 

  • Goldberg DP, Bridges P, Duncan-Jones P & Grayson D. Dimensions of neuroses seen in primary care settings. Psychol Med 17, 461–470, 1987

    PubMed  CAS  Google Scholar 

  • Graeff PG, Guimaraes FS, Andrade TC & Deaxin JF. The role of 5-HT in stress, anxiety and depression. Pharmacol Biochem Behav 54, 129–141, 1996

    PubMed  CAS  Google Scholar 

  • Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65 (3): 319–395, 1995

    PubMed  CAS  Google Scholar 

  • Griebel G, Perrault G & Sanger DJ. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154, 526 in anxiety models in rodents. Psychopharmacology 138, 55–66, 1998

    PubMed  CAS  Google Scholar 

  • Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 82, 1, 1–61, 1999

    PubMed  CAS  Google Scholar 

  • Guidotti A, Toffano G & Costa E. An endogenous protein modulates the affinity of GABA and benzodiazepine receptors in rat brain. Nature 275, 553–555, 1978

    PubMed  CAS  Google Scholar 

  • Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97 (11), 6079–6084, 2000

    PubMed  CAS  Google Scholar 

  • Haefely W & Pole C. Electrophysiological studies on the interaction of anxiolytic drugs with GABAergic mechanisms. In: JB Malick, SJ Enna & HI Yamamura (eds): Anxiolytics: Neurochemical, behavioural and clinical perspectives. New York: Raven Press, 113–115, 1983

    Google Scholar 

  • Haefely W. biological basis of drug-induced tolerance, rebound and dependence. Contribution of recent research on benzodiazepines. Pharmacology 19, 353–361, 1986

    CAS  Google Scholar 

  • Handley SL. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 66 (1):103–48, 1995

    PubMed  CAS  Google Scholar 

  • Harandi M, Aguera M, Gamrani H, Didier M, Maitre M, Calas A & Belin ME Gammaaminobutyric acid and 5-hydroxytryptamine. Interrelationship in the rat nucleus dorsalis: Combination of radiographic and immunocytochemical technique at light and electron microscope levels. Neuroscience 21, 237–251, 1987

    PubMed  CAS  Google Scholar 

  • Harper PS, Harley HG, Reardon W & Shaw DJ. Anticipation in myotonic dystrophy: new light on an old problem. Am J Hum Genet 51, 10–16, 1992

    PubMed  CAS  Google Scholar 

  • Harro J, Vasar E & Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci 14 (6): 244–249, 1993

    PubMed  CAS  Google Scholar 

  • Hashimoto S, Inoue T & Koyama T. Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats. Eur J Pharmacol 378, 23–30, 1999

    PubMed  CAS  Google Scholar 

  • Heilig M, Koob GF, Ekman R & Britton KT. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Pharmacol Sci 17, 80–85, 1994

    CAS  Google Scholar 

  • Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept 41, 61–69, 1995

    Google Scholar 

  • Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH & Tecott LH. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA 95 (25):15049–15054, 1998

    PubMed  CAS  Google Scholar 

  • Henin A & Kendall PC. Obsessive-compulsive disorder in childhood and adolescence. In: TH Ollendick & RJ Prinz (eds): Advances in clinical child psychology, Vol. 19. New York: Plenum Press, 75–131, 1997

    Google Scholar 

  • Heninger GR, Charney DS & Price LH. Alpha-2 adrenergic receptor sensitivity in depression. Arch Gen Psychiatry 45, 718–726, 1988

    PubMed  CAS  Google Scholar 

  • Hoehn-Saric R & McLeod DR. Anxiety and arousal: physiological changes and their perception. J Affect Disord 61, 217–224, 2000

    PubMed  CAS  Google Scholar 

  • Hokfelt T, Skirboll L, Everitt B, Meister B, Brownstein M, Jacobs T, Faden A, Kuga S, Goldstein M & Markstein R. Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides. Ann NY Acad Sci 448, 255–274, 1985

    PubMed  CAS  Google Scholar 

  • Hollander E, DeCaria C, Nitescu A, Cooper T, Stover B, Gully R, Klein DF & Liebowitz MR. Noradrenergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Res 37 (2), 161–177, 1991.

    PubMed  CAS  Google Scholar 

  • Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR & Humphrey PPA. VII International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46, 157–203, 1994

    PubMed  CAS  Google Scholar 

  • Jenck F, Moreau J-L, Berendsen HHG, Boes M, Broekkamp CLE, Martin JR, Wichmann J & Van Delft AML. Antiaversive effects of 5HT2c receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8, 161–168, 1998

    PubMed  CAS  Google Scholar 

  • Jerabek I, Lavallée YJ, Jolicoeur FB & Boulenger J Ph. Cholécystokinine et anxiété. II. La CCK-4, modèle expérimental, des attaques de panique. Ann Psychiatr 11, 36–41, 1996

    Google Scholar 

  • Johnson MR, Marazziti D, Brawman-Mintzer O, Emmanuel NP, Ware MR, Morton WA, Rossi A, Cassano GB & Lydiard RB. Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia. Biol Psychiatry 43, 306–309, 1998

    PubMed  CAS  Google Scholar 

  • Jolas T, Schreiber R, Laporte AM, Chastanet M, De Vry J, Glaser J, Adrien J & Hamon M. Are postsynaptic 5-HT(1A) receptors involved in the anxiolytic effect of 5-HT(1A) receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat? J Pharmacol Exp Ther 272, 920–929, 1995

    PubMed  CAS  Google Scholar 

  • Johnston GAR. GABAc receptors: relatively simple transmitter-gated ion channels? Trends Pharmacol Sci 17, 319–323, 1996

    PubMed  CAS  Google Scholar 

  • Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, Fisher S & Frankenthaler LM. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry 43, 79–85, 1986

    PubMed  CAS  Google Scholar 

  • Kask A, Nguyen HP, Pabst R & Von Hörsten S. Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience 104, 799–806, 2001

    PubMed  CAS  Google Scholar 

  • Kask A, Rago L & Harro J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226: antagonism with diazepam. Eur J Pharmacol 317, R3–R4, 1996

    PubMed  CAS  Google Scholar 

  • Katerndahl DA & Realini JP. Lifetime prevalence of panic states. Am J Psychiatry 150,246–249, 1993

    PubMed  CAS  Google Scholar 

  • Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry 57 (10), 11–18, 1996

    PubMed  Google Scholar 

  • Kehne JH, Coverdale S, McCloskey TC, Hoffman DC & Cassella JV. Effects of the CRF (1) receptor antagonist, CP 154,526 in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39, 1357–1367, 2000

    PubMed  CAS  Google Scholar 

  • Kellner M, Herzog L, Yassouridis A, Holsboer F & Wiedemann K. Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J Psychiatry 152, 1365–1367, 1995

    PubMed  CAS  Google Scholar 

  • Kendler KS, Davis CG & Kessler RC. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br J Psychiatry 170, 541–548, 1997

    PubMed  CAS  Google Scholar 

  • Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt KE et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640–1645, 1998

    PubMed  CAS  Google Scholar 

  • Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matzurawolfe D, Lines C & Reines S. A placebo-controlled trial of L-365, 260, a CCKB antagonist, in panic disorder. Biol Psychiatry 37, 462–466, 1995

    PubMed  CAS  Google Scholar 

  • Kreiss DS & Lucki I. Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei. J Pharmacol Exp Ther 269 (3):1268–1279, 1994

    PubMed  CAS  Google Scholar 

  • Kumor KM, Haertzen CA, Johnson RE, Kocher T & Jasinski D. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238 (3): 960–968, 1986

    PubMed  CAS  Google Scholar 

  • Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they jus-tified? European Neuropsychopharmacology 9 (Suppl), S399–S405, 1999

    PubMed  CAS  Google Scholar 

  • Lambert JJ, Belelli D, Hill-Yenning C & Peters JA. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 16 (9): 295–303, 1995

    PubMed  CAS  Google Scholar 

  • Leckman JF, Weissman M, Merikangask KR, Pauls DL & Prusoff BA. Panic disorder and major depression: Increased risk of depression, alcoholism, panic and phobic disorders in families of depressed probands with panic disorders. Arch Gen Psychiatry 40, 1055–1060,1983

    PubMed  CAS  Google Scholar 

  • Le Doux JE. Information flow from sensation to emotion: plasticity in the neural computation of stimulus value. In: M Gabriel, J Moore (eds): Learning and computational neurosciences: Foundations of adaptive networks. Cambridge, Mass: MIT, 1990

    Google Scholar 

  • Lee YM, Beinborn M, McBride EW, Lu M, Kolakowski LF Jr & Kopin AS. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem 268, 8164–8169, 1993

    PubMed  CAS  Google Scholar 

  • Lee CR, Plosker GL & McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as an antiemetic. Drugs 46, 925–943, 1993

    PubMed  CAS  Google Scholar 

  • Lesch KP, Wiesmann M, Hoh A, Muller T, Disselkamp Tietze J, Osterheider M & Schulte HM. 5HT1A receptor effector system responsivity in panic disorder. Psychopharmacology (Berl), 106, 111–117, 1992

    CAS  Google Scholar 

  • Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH & Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527–1531, 1996

    PubMed  CAS  Google Scholar 

  • Loehlin JC. Partitioning environmental and genetic contributions to behavioral development. American Psychologist 44 (10):1285–1292, 1989

    PubMed  CAS  Google Scholar 

  • Lopez-Rubalcava C, Saldivar A, Fernandez-Guasti A. Interaction of GABA and serotonin in the anxiolytic action of diazepam ad serotonin in the anxiolytics. Pharmacol Biochem Behav 43, 433–440, 1992

    PubMed  CAS  Google Scholar 

  • Lucki I, Singh A & Kreiss DS. Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav 18 (1): 85–95, 1994

    CAS  Google Scholar 

  • Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy J-M, Rülicke T, Bluethmann H, Möhler H & Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 260, 131–134, 2000

    Google Scholar 

  • Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widner U & Moreau J-L. A non-peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 309, 195–200, 1996

    PubMed  CAS  Google Scholar 

  • Macdonald RL & Olsen RW. GABAA receptor channels. Annu Rev Neurosci 17, 569–602, 1994

    PubMed  CAS  Google Scholar 

  • MacMillan H & Steiner M. A Atrial natriuretic factor. Does it have a role in psychiatry? Biol Psychiatry 35, 272–277, 1994

    PubMed  CAS  Google Scholar 

  • Maggi CA, Patacchini R, Rovero P & Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 13, 23–93, 1993

    PubMed  CAS  Google Scholar 

  • Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T & Nutt DJ. Decreased brain GABAA-benzodiazepine receptor binding in panic disorder. Arch Gen Psychiatry 55, 715–720, 1998

    PubMed  CAS  Google Scholar 

  • Martin A, Kaufman J & Charney D. Pharmacotherapy of early-onset depression. Update and new directions. Child Adolesc Psychiatr Clin N Am 9, 135–157, 2000

    PubMed  CAS  Google Scholar 

  • Mazzanti CM, Lappalainen J, Long JC, Bengel D, Naukkarinen H, Eggert M, Virkkunen M, Linnoila M & Goldman D. Role of the serotonin transporter promoter polymorphism in anxiety-related traits. Arch Gen Psychiatry 55, 936–940, 1998

    PubMed  CAS  Google Scholar 

  • Marazziti D, Rotondo A, Martini C, Giannaccini G, Lucacchini A, Panciolo-Guadagnucci ML, Diamond BI, Borison R & Cassano GB. Changes in peripheral benzodiazepine receptors in patients with panic disorder and obsessive-compulsive disorder. Neuropsychobiology 29, 8–11, 1994

    PubMed  CAS  Google Scholar 

  • Martin JR, Bös M, Jenck F, Köhler C, Moreau JL, Sleight A, Stadler H & Wichmann J. 5HT2c receptor agonists and antagonists in animal models of anxiety. Eur Neuropsychopharmacol 5, 209, 1995

    CAS  Google Scholar 

  • Martin DC, Introna RP & Aronstam RS. Fentanyl and sulfentanyl inhibit agonist binding to 5HT1A receptors in membranes from rat brain. Neuropharmacology 30, 323–327, 1993

    Google Scholar 

  • Martin WR. Pharmacology of opioids. Pharmacol Rev 35 (4): 283–323, 1983

    PubMed  CAS  Google Scholar 

  • Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383 (6603): 819–823, 1996

    PubMed  CAS  Google Scholar 

  • Mattila M, Seppala T & Mattila MJ. Combined effects of buspirone and diazepam on objective and subjective tests of performance in healthy volunteers. Clin Pharmacol Ther 40, 620–626, 1986

    PubMed  CAS  Google Scholar 

  • Matussek N, Ackenheil M, Hippius H, Muller F, Schroder HT, Schultes H & Wasilewski B. Effect of clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res 2 (1): 25–36, 1980

    PubMed  CAS  Google Scholar 

  • McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR & Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51, 302–308, 1994

    PubMed  CAS  Google Scholar 

  • McKerman RM et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor a1 subtype. Nature Neurosci 3, 587–592, 2000

    Google Scholar 

  • McNaughton N. Cognitive dysfunction resulting from hippocampal hyperactivity — a possible cause of anxiety disorder? Pharmacol Biochem Behav 56, 603–611, 1997

    PubMed  CAS  Google Scholar 

  • McNicoll C, Bill DJ & Fletcher A. Potentiation of SSRI-induced inhibition of mouse marble burying by a selective 5-HT1A antagonist. J Psychopharmacol 9, A29, 1995

    Google Scholar 

  • Misane I & Ogren SO. Multiple 5-HT receptors in passive avoidance: comparative studies of p-chloroamphetamine and 8-OH-DPAT. Neuropsychopharmacology 22 (2): 168–190, 2000

    PubMed  CAS  Google Scholar 

  • Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW & Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43 (3): 320–327, 1993

    PubMed  CAS  Google Scholar 

  • Nemeroff CB. The preeminent role of early untoward experience on vulnerability to major psychiatric disorders: The nature-nurture controversy revisited and soon to be resolved. Mol Psychiatry 4, 106–108, 1999

    PubMed  CAS  Google Scholar 

  • Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 60 (Supp122), 12–17, 1999

    PubMed  CAS  Google Scholar 

  • Nutt DJ. Altered central alpha-2 sensitivity in panic disorder. Arch Gen Psychiatry 46, 165–169, 1989

    PubMed  CAS  Google Scholar 

  • Oberto A, Panzica G, Altruda F & Eva C. Chronic modulation of the GABAA receptor complex regulates Y1 receptor gene expression in the medial amygdala of transgenic mice. Neuropharmacology 39, 227–234, 2000

    PubMed  CAS  Google Scholar 

  • Ohara K, Suzuki Y, Ochiai M, Yoshida K, Ohara K. Age of onset anticipation in anxiety disorders. Psychiatry Res 89, 215–221, 1999

    PubMed  CAS  Google Scholar 

  • Okuyama S, Chaki S, Kawashima N, Yoshiko S, Ogawa S-I, Nakazato A, Kumagai T, Ojubo T & Tomisawa K. Receptor binding, behavioral, and electrophysiological profiles of non-peptide corticotropin-releasing factor subtype 1 receptor antagonist CRA 1000 and CRF1001. J Pharmacol Exp Ther 289, 926–935, 1999

    CAS  Google Scholar 

  • Olivier B, van Wijngaarden I & Soudijn W. 5-HT3 receptor antagonists and anxiety: a preclinical and clinical review. Eur Neuropsychopharmacol 10, 77–95, 2000

    PubMed  CAS  Google Scholar 

  • Olsen RW & Venter JC. Benzodiazepine-GABA receptors and chloride channels: Structural and functional properties. New York: Alan R. Liss, 1985

    Google Scholar 

  • Owens MJ & Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40 (2): 288–295, 1994

    PubMed  CAS  Google Scholar 

  • Owens MJ & Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 31, 425–473, 1991

    Google Scholar 

  • Pande AC. Lack of efficacy of a cholecystokinin-B antagonist in anxiety disorders. Biol Psychiatry 42, 11–19, 1997

    Google Scholar 

  • Parks CL, Robinson PS, Sibille E, Shenk T & Toth M. Increased anxiety of mice lacking the serotoninlA receptor. Proc Natl Acad Sci USA 95, 10734–10739, 1998

    PubMed  CAS  Google Scholar 

  • Patchev VK, Montkowski A, Rouskova D, Koranyi L, Holsboer F & Almeida OF. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest 99 (5): 962–966, 1997

    PubMed  CAS  Google Scholar 

  • Paul SM & Purdy RH. Neuroactive steroids. FASEB J 6 (6): 2311–2322, 1992

    PubMed  CAS  Google Scholar 

  • Paulson HL & Fischbeck KH. Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 19, 79–107, 1996

    PubMed  CAS  Google Scholar 

  • Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P &Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 92, 2969–2973, 1995

    PubMed  CAS  Google Scholar 

  • Pfeiffer A, Brantl V, Herz A & Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science 233 (4765): 774–776, 1986

    PubMed  CAS  Google Scholar 

  • Pichot W, Hansenne M, Gonzalez Moreno A & Ansseau M. Growth hormone response to apomorphine in panic disorder: comparison with major depression and normal controls. Eur Arch Psychiatry Clin Neuroscience 245 (6): 306–308, 1995

    CAS  Google Scholar 

  • Pigott TA & Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60 (2): 101–106, 1999

    PubMed  CAS  Google Scholar 

  • Piot O, Betschart J, Grall I, Ravard S, Garret C & Blanchard JC. Comparative behavioural profile of centrally administered tachykinin NKl, NK2 and NK3 receptor agonists in the guinea-pig. Br J Pharmacol 116, 2496–2502, 1995

    PubMed  CAS  Google Scholar 

  • Pollard GT & Howard JL. Effects of drugs on punished behavior: pre-clinical tests for anxiolytics. Pharmacol Ther 45, 104–424, 1990

    Google Scholar 

  • Porter JH, Wiley JL &d Balster RL. Effects of phencyclidine-like drugs on punished behavior in rats. J Pharmacol Exp Ther 248, 991, 1989

    Google Scholar 

  • Plomin R, Owen MJ & McGuffin P. The genetic basis of complex human behaviors. Science 264 (5166): 1733–1739, 1994

    PubMed  CAS  Google Scholar 

  • Privette TH & Terrian DM. Kappa opioid agonists produce anxiolytic-like behaviors on the elevated plus-maze. Psychopharmacology 118, 444–450, 1995

    PubMed  CAS  Google Scholar 

  • Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JI, Brunner D & Hen R. Serotonin receptor 1A knockout: An animal model of anxiety-related disorder. Proc Natl Acad Sci USA 95, 14476–14481, 1998

    PubMed  CAS  Google Scholar 

  • Regoli D, Boudon A & Fauchere JL. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 46, 551–599, 1994

    PubMed  CAS  Google Scholar 

  • Reinhard JJ, Bannon MJ and Roth RH. Acceleration by stress of dopamine synthesis and metabolism in prefrontal cortex: antagonism by diazepam. Naunyn-Schmiedebergs Arch Pharmacol 318, 374–377, 1982

    PubMed  CAS  Google Scholar 

  • Reisine T & Pasternak G. In: JG Harman & LE Limbird (eds): Goodman and Gilman’s The pharmacological basis of therapeutics. McGraw-Hill, 521–555, 1996

    Google Scholar 

  • Rex A, Barth T, Voigt J-P, Domeney AM & Fink H. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neurosci Lett 172, 139–142, 1994

    PubMed  CAS  Google Scholar 

  • Rickels K, Schweizer E, Csanalosi I, Case WG & Chung H. Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 45, 444–450, 1988

    PubMed  CAS  Google Scholar 

  • Rickels K, Downing R, Schweizer E & Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 50, 884–895, 1993

    PubMed  CAS  Google Scholar 

  • Rocca P, Beoni AM, Eva C, Ferrero P, Zanalda E & Ravizza L. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biol Psychiatry 43 (10), 767–773, 1998.

    PubMed  CAS  Google Scholar 

  • Rodgers RJ & Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol Biochem Behav 59 (1): 221–232, 1998

    PubMed  CAS  Google Scholar 

  • Roozendaal B, Koolhaas JM & Bohus B. Central amygdaloid involvement in neuroendocrine correlates of conditioned stress responses. J Neuroendocrinol 4, 46–52, 1992

    Google Scholar 

  • Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM & Schwartz JC. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci USA 90 (18): 8547–8551, 1993

    PubMed  CAS  Google Scholar 

  • Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H & Mohler H. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401 (6755): 796–800, 1999

    PubMed  CAS  Google Scholar 

  • Sanchez C. Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white text box. Pharmacol Toxicol 77 (1): 71–78, 1995

    PubMed  CAS  Google Scholar 

  • Sanger DJ & Jackson A. Effects of phencyclidine and other N-methyl-D-aspartate antagonists on the schedule-controlled behavior of rats. J Pharmacol Exp Ther 248, 1215, 1989

    PubMed  CAS  Google Scholar 

  • Schechter LE, Bolanos FJ, Gozlan H, Lanfumey L, Haj-Dahmane S, Laporte AM, Fattaccini CM & Hamon M. Alterations of central serotonergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther 255, 1335–1347, 1900

    Google Scholar 

  • Schofield PR, Darlison MG, Fujita N, Burt DR, Stephenson FA, Rodriguez H, Rhee LM, Ramachandran J, Reale V & Glencorse TA. Sequence and functional expression of the GABA A receptor shows a ligand-gated receptor super-family. Nature. 328 (6127): 221–227, 1987

    PubMed  CAS  Google Scholar 

  • Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Farach S, Schmidt AW, Seeger T et al. CP-154,526: a potent and selective n on-peptide antagonist of corticotropin-releasing factor receptors. Proc Natl Acad Sci USA 93, 10477–10482,1996

    PubMed  CAS  Google Scholar 

  • Siever LJ, Uhde TW, Silberman EK et al. Growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls. Psychiatry Res 6, 171–183, 1982

    PubMed  CAS  Google Scholar 

  • Sieghart W. Structure and pharmacology of g-aminobutyric acidA receptor subtypes. Pharmacol Rev 47, 181–233, 1995

    PubMed  CAS  Google Scholar 

  • Sim-Selley LJ, Vogt LJ, Xiao R, Childres SR & Selley DE. Region-specific changes in 5-HT1A receptor-activated G-proteins in rat brain following chronic buspirone. Eur J Pharmacol 389, 147–153, 2000

    PubMed  CAS  Google Scholar 

  • Singh L, Lewis AS, Field MJ, Hughes J & Woodruff GN. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 88, 1130–1133, 1991

    PubMed  CAS  Google Scholar 

  • Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA & Woodruff GN. The behavioural properties of C1988, a selective cholecystokinin B receptor antagonist. Br J Pharmacol 104, 239–245, 1991a

    CAS  Google Scholar 

  • Sivilotti L & Nistri A. GABA receptor mechanisms in the central nervous system. Prog Neu-rol 36, 35–92, 1991

    CAS  Google Scholar 

  • Smith GW, Aubry J-M, Dellu F, Contrarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20, 1093–1102, 1998

    PubMed  CAS  Google Scholar 

  • Söderpalm B & Engel JA. Does the p-CPA induced anticonflict effect involve activation of the GABAA/benzodiazepine chloride ionophore receptor complex? J Neural Transm 76, 145–153, 1989

    PubMed  Google Scholar 

  • Sommermeyer H, Schreiber R, Greuel JM, De Vry J & Glaser T. Anxiolytic effects of the 5-HT1A receptor agonist ipsapirone in the rat: neurobiological correlates. Eur J Pharmacol 240 (1): 29–37, 1993

    PubMed  CAS  Google Scholar 

  • Starcevic V, Uhlenhuth EH, Fallon S & Pathak D. Personality dimensions in panic disorder and generalized anxiety disorder. J Affect Disord 37, 75–79, 1996

    PubMed  CAS  Google Scholar 

  • Anokhin A, Yping M, Schalt E & Vogel F. Localization of a gene for the human low-voltage EEG on 20q and genetic heterogeneity. Genomics 12(1), 69–73, 1992

    PubMed  Google Scholar 

  • Stoessl AJ, Brackstone M, Rajakumar N & Gibson CJ. Pharmacological characterization of grooming induced by a selective NK1 tachykinin receptor agonist. Brain Res 700, 115–120, 1995

    PubMed  CAS  Google Scholar 

  • Stout SC, Kilts CD & Nemeroff CB. Neuropetides and stress: preclinical findings and implications for pathophysiology. In: MJ Friedman, S Charney, AY Deutsch (eds): Neurobiological and clinical consequences of stress: From normal adaptation to post-traumatic stress disorder. Philadelphia: Lippincott Raven, 1995

    Google Scholar 

  • Sullivan GM, Copland JD & Gorman JM. Psychoneuroendocrinology of anxiety disorders. Psychoneuroendocrinology 21, 2, 397–412, 1998

    CAS  Google Scholar 

  • Svrakic MD, Przybeck TR & Cloninger CR. Mood states and personality traits. J Affect Disord 24, 217–226, 1992

    PubMed  CAS  Google Scholar 

  • Tancer ME, Stein MB & Uhde TW. Growth hormone response to intravenous clonidine in social phobia: Comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 34, 591–595, 1993

    PubMed  CAS  Google Scholar 

  • Takahashi LK, Ho SP, Livanov V, Graciani N & Arneric SP. Antagonism of CRF2 receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902, 135–142, 2001

    PubMed  CAS  Google Scholar 

  • Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Reul HM, Stalla GK, Blanquet V, Stecker T, Holsboer F & Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19, 162–166,1998

    PubMed  CAS  Google Scholar 

  • Trappler B. Treatment of obsessive-compulsive disorder using clomipramine in a very old patient. Ann Pharmacotherapy 33 (6): 686–690, 1999

    CAS  Google Scholar 

  • Uhlenhuth EH, Baiter MB, Ban TA & Yang K. Trends in recommendations for the pharma-cotherapy of anxiety disorders by an international expert panel, 1992–1997. Eur Neuropsychopharmacol 9 (6), S393–S398, 1999

    PubMed  CAS  Google Scholar 

  • Van Megen HJ, Westenberg HG, den Boer JA & Kahn RS. Cholecystokinin in anxiety. Eur Neuropsychopharmacology 6, 263–280, 1996

    Google Scholar 

  • Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH & Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 321 (6073): 864–866, 1986

    PubMed  CAS  Google Scholar 

  • Vivian JA, Barros HM, Manitiu A & Miczek KA. Ultrasonic vocalizations in rat pups: modulation at the gamma-aminobutyric acidA receptor complex and the neurosteroid recognition site. J Pharmacol Exp Ther 282 (1): 318–325, 1997

    PubMed  CAS  Google Scholar 

  • Wank SA, Pisegna JR & de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure and functional expression in rat, guinea pig and human. Ann NY Acad Sci 713, 49–66, 1994

    PubMed  CAS  Google Scholar 

  • Ward HE, Johnson EA, Salm AK & Birkle DL. Effects of prenatal stress on defensive withdrawal behavior and corticotropin releasing factor systems in rat brain. Physiol Behav 70, 359–366, 2000

    PubMed  CAS  Google Scholar 

  • Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu H-G, Joyce PR, Karam EG, Lee C-K, Lellouch J et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54, 305–309, 1997

    PubMed  CAS  Google Scholar 

  • Westenberg HG. Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry 60 (17), 4–8; discussion 46–8, 1999

    PubMed  CAS  Google Scholar 

  • Widerlöv E, Lindstrom LH, Wahlestedt C & Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22, 69–79, 1988

    PubMed  Google Scholar 

  • Wieland S, Lan NC, Mirasedeghi S & Gee KW. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3-alpha-ol-20-one. Brain Res 565, 263–268, 1991

    PubMed  CAS  Google Scholar 

  • Wieland S, Beluzzi JD, Stein L & Lan NC. Comparative behavioral characterization of the neuroactive steroids 3 alpha-OH, 5 alpha-pregnan-20-one and 3 alpha-OH, 5 betapregnan-20-one in rodents. Psychopharmacology 118, 65–71, 1995

    PubMed  CAS  Google Scholar 

  • Wilde MI & Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 52, 773–794, 1996

    PubMed  CAS  Google Scholar 

  • Willetts J, Balster RL & Leander JD. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11, 423, 1990

    PubMed  CAS  Google Scholar 

  • Wiley JL, Cristello AF & Balster RL. Effects of site-selective receptor antagonists in an ele-vated plus-maze model of anxiety in mice. Eur J Pharmacol 294, 101–107, 1995

    CAS  Google Scholar 

  • Wright IK, Upton N & Marsden CA. Effect of established and putative anxiolytics on extra-cellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behavior on the elevated X-maze. Psychopharmacol (Berl) 109, 338–346, 1992

    CAS  Google Scholar 

  • Yarker YE & McTavish D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 48, 761–793, 1994

    PubMed  CAS  Google Scholar 

  • Zadina JE, Hackler L, Ge L-J & Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (6624), 499–502, 1997

    PubMed  CAS  Google Scholar 

  • Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M & Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatric Res 34 (3): 171–181, 2000

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 127 rue Henri Prou, Les Clayes Sous Bois, 78340, France

    Dr. Gérard Emilien

  2. Department of Pharmacology and Therapeutics, University College Cork, Ireland

    Prof. Timothy Dinan

  3. Kuopion Psykiatripalvelu Oy, Psychiatric Research Clinic of Kuopio, Asemakatu 46, Kuopio, FIN-70110, Finland

    Dr. Ulla Marjatta Lepola

  4. 23 Rue Raynouard, Paris, 75016, France

    Dr. Cécile Durlach

Authors
  1. Dr. Gérard Emilien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Timothy Dinan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. Ulla Marjatta Lepola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. Cécile Durlach
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Basel AG

About this chapter

Cite this chapter

Emilien, G., Dinan, T., Lepola, U.M., Durlach, C. (2002). Biological basis of anxiety and strategies for pharmacological innovation. In: Anxiety Disorders. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8157-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8157-9_2

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9460-9

  • Online ISBN: 978-3-0348-8157-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation